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Radiotherapy (RT) is our preferred modality for local palliation of metastatic soft tissue sarcoma (STS). A short and intense course
of RT is usually needed for rapid palliation and local control of metastatic disease. Seventeen patients at a median age of 61
had symptomatic metastatic sarcoma and required rapid palliation. The symptoms related to the metastases were either pain or
discomfort.Allpatientsweretreatedbyashortandintensivecourseofadministration:39Gyweregivenin13fractionsof3Gy/day,
5 times a week. Median follow-up period was 25 weeks. The treatment was well tolerated. Acute side eﬀects included grade one
skin toxicity. No wound complications were noted among those undergoing surgery. Late side eﬀects included skin pigmentation
and induration of irradiated soft tissues. Durable pain control was achieved in 12 out 15 cases treated for gross metastases. Tumor
progression was seen in the 3 other cases within a period of two to nine months. Among 5 lesions which were irradiated as an
adjunctive treatment following resection, no local recurrence was observed. The results of this series, although limited in size,
point to the safety and feasibility of hypofractionated RT for palliation of musculoskeletal metastases from sarcoma
1.Introduction
Soft tissue sarcomas (STS) of the extremities in young or
good-performance-status patients are currently approached
by limb sparing surgery (LSS) followed by radiation therapy
(RT) [1]. We have previously reported a series of 133 adult
patients with intermediate or high-grade limb STS who were
approached by LSS + RT [2] .A l o n gw i t ho t h e r s ,w eh a v e
previously demonstrated that a schedule of 1.8Gy/fraction,
5 fractions per week to a midplane dose of 63Gy, or 70Gy
in the setting of marginal excision or involved margins, was
feasible, tolerable and eﬃcient [2]. Locally advanced cases,
involving the neurovascular bundle or the underlying bone,
may be treated with surgery following induction chemother-
apy [3] or isolated limb perfusion with tumor-necrosis-
factor-α [4], or by deﬁnitive RT [5]o rb ya m p u t a t i o n[ 6].
Locally recurrent or metastatic disease may be palliated by
systemic chemotherapy, surgery, and RT. Amputation has
been advocated as a palliative procedure for symptomatic
locally advanced disease that has already failed to respond
to radiation therapy, chemotherapy, and limited surgery [7].
RT is our preferred modality for local palliation of metastatic
disease, irrespective of whether systemic chemotherapy is
employed. While a protracted course of RT may be given
as postoperative adjuvant treatment, a short and intense
course of RT is usually needed for rapid palliation and
local control of metastatic disease. Our impression was that
the commonly applied RT doses for palliation of other
malignancies were not adequate for palliation of sarcoma
metastases. Many patients required reirradiation of lesions
(unpublisheddata).Inthispaperwereportafeasibilitystudy
of 39Gy administered in 13 fractions of 3Gy each, over 132 Sarcoma
workingdays(ﬁvedaysperweek),inagroupofpatientswith
metastatic sarcoma.
2.MaterialsandMethods
2.1. Patients. Seventeen patients, 8 women and 9 men, at a
median age of 61 years (range 53–95 years) had symptomatic
metastatic sarcoma, and required rapid palliation. The types
of sarcoma included liposarcoma (5 patients), pleomorphic
sarcoma (3), chondrosarcoma (2), synovial sarcoma (1),
bone sarcoma (1 Ewing sarcoma of pelvis, 1 leiomyosarcoma
of bone), leiomyosarcoma (2), and unclassiﬁed sarcoma (2).
In total there were 20 sites of involvement by metastatic
disease: trunk (chest wall, groin, axilla)—13 cases, limb- 7
cases. The symptoms related to the metastases were either
pain or discomfort in all the patients. In 15 cases the RT
was the only modality for local palliation and in 5 cases RT
was given following metastasectomy with close or involved
margins.
2.2. Radiation Therapy. All patients underwent CT simu-
lation (Phillips Brilliance Big Bore). The positioning and
immobilization of patients was individualized as a function
of tumor location. Beams were designed to achieve coverage
of the clinical treatment volume (CTV). CTV included the
gross tumor volume (GTV), that in cases of palliation mostly
included the viable and visible tumor with margins of 1.5–
2cm, and in cases of postmetastasectomy treatment after
wide or marginal resections, included the tumor in it’s
location before the surgery. In those cases the CTV was
based on the preoperative CT scan or MRI and clips which
surgeons placed at the tumor bed and its edges. Special
attention in postoperative cases was devoted to the linear
borders of the ﬁelds so as to be at least 4 to 5cm beyond
the edges of tumor bed. Treatment planning was carried
out with the XiO system (CMS Corporation: St. Louis,
MO, USA) and was according to requirements of ICRU-50.
Before the start of treatment each patient had veriﬁcation
of portals (Elekta I-View GT- IVIEW02). The radiation
was provided by ELEKTA linacs (Stockholm, Sweden) with
energies of 6 or 18MV. Patients were assessed for side
eﬀects and compliance with treatment on a weekly basis
during therapy, at the end of treatment, and every 3 months
thereafter. All patients were treated by a short and intensive
course of administration; 39Gy were given in 13 fractions
of 3Gy/day, 5 times a week. This fractionation regimen was
selected to achieve a meaningful dose based on α-β modeling
(vide infra).
3. Results
The median follow-up period was 25 weeks (range: 12–
89 weeks). Thirteen fractions were given over 13–16 days.
T h et r e a t m e n tw a sw e l lt o l e r a t e d .A c u t es i d ee ﬀects included
grade 1 skin reaction (faint erythema as per CTC Version
2.0) (16) in all cases. No wound complications were noted.
D u r a b l ep a i nc o n t r o lw a sa c h i e v e di n1 2o u t1 5c a s e st r e a t e d
for gross metastases. Tumor progression was seen in the 3
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other cases within a period of two to nine months. Among
the 5 lesions which were irradiated post-metastasectomy, no
local recurrence was observed.
All patients were invited back for follow-up visits to
the multidisciplinary sarcoma clinic on a quarterly basis
where physical exam and review of imaging was performed
(including RECIST criteria) (15). By evaluating tumor
response in this manner we were able to determine time to
local progression.
Fourteen patients were alive at the end of the observation
period (Kaplan-Meir analysis—Figure 1 ).
4. Discussion
Sarcomas are usually considered, at best, moderately radio
responsive tumors. RT doses at range of 60–70Gy are usually
needed to be delivered in order to eradicate microscopic
disease, while doses of 50Gy can yield similar results for
other malignancies such as breast or rectal cancer. One of the
biological characteristics of sarcoma cells is their relatively
low (−0.5–5.4) α-β ratio [8]. This ratio, theoretically, may
justify the use of larger-than-standard fractionation in order
to achieve signiﬁcant cell-kill by RT. We used a popular for-
mula for standardization of diﬀerent fractionation regimens:
BED = ND × (1+D/α-β ratio), when BED is dose equivalent
to standard fractionation of 1.8–2Gy, N is the number of
fractions, and D is the given fraction dose [8]. To achieve the
dose equivalent to 60–70Gy we decided to use 13 fractions
of mildly elevated daily dose of 3Gy. Assuming the alpha-
beta ratio of Sarcoma cells as 4 our calculation of BED is as
following: 13 ×3 (1+ 3/4) = 68Gy.
The results of this series, although limited in size, point
to the safety and feasibility of hypofractionated RT for
palliation of musculoskeletal metastases from sarcoma. The
chosen fractionation regime appears to achieve adequate
local and symptom control in the majority of patients during
the short to medium term. While a protracted course of
RT is applied for post-operative adjuvant RT as part of LSS
approach, a short and intense course may be needed for
local control and palliation. In the presence of metastatic
disease, especially when the expected survival is limited, itSarcoma 3
Table 1: Patient Characteristics.
Pt Age Sex Site Pathology Indication of Treatment DDD TTLP TTDP
1 53 F Chest LMC Adjuvant to surgery 13 61
2 78 F Thigh Pleomorphic Adjuvant to surgery 13
3 65 M Groin HGSTS Palliation 13
4 71 M Pelvis Myxoid Chondrosarcoma Palliation 13 266
5 86 F Calf Chondrosarcoma Palliation 13
6 68 F Pelvis MFH Palliation 13 413
7 41 M Chest and thigh SS Palliation 13 196 247
8 59 F Thigh Bone LMS Palliation 16 56
9 44 M Chest HGSTS Palliation 13 180
10 49 M Thigh MFH Adjuvant to surgery 15 48
11 51 F Foot HGSTS Palliation 14
12 50 M Pelvis LMS Palliation 13
13 60 M Groin LMS Adjuvant to surgery 13 90
14 27 M Pelvis Ewing Palliation 13 5
15 51 F Chest LMS Palliation 13 12 12
16 80 F Calf, groin, axilla HGSTS Palliation 13
17 95 M Thigh LMS Adjuvant to surgery 13 270
Key:Pt: Patient; F: Female; M: Male; LMS: Leiomyosarcoma; HGSTS: High Grade Soft Tissue Sarcoma; MFH: Malignant Fibro Hystiocytoma; SS: Synovial
Sarcoma; DDD: Duration of dose delivery; TTLP: time to local progression; TTDM: time to distant progression (the latter 3 parameters all measured in days).
is important to deliver the RT over a short period, and
avoid the inconvenience associated with a multifractionated
regimen of radiotherapy. This issue may be particularly true
for elderly and debilitated patients, in whom a short course
of RT may be the only practical option for a local palliation.
All the patients received the RT during an acceptable period
of time, and well tolerated the therapy.
Hypofractionation as a part of neoadjuvant chemo-
radiotherapy for STS was popularized by Eilber et al. [3],
who applied a regimen of 10 fractions of 3.5Gy each.
The rationale was based on the observation that irradiated
melanoma cell lines had a large initial shoulder on their
survival curve. The potential radio resistance of melanoma
and, by extension, sarcoma, was attributed to tumor cell
capacity for sublethal damage repair, as implied by this
shoulder [9].
The histological response of dose intense chemotherapy
with preoperative hypofractionated radiotherapy in patients
with STS was further investigated by Ryan et al. [10].
T h e yr e p o r t e dah i g hr a t eo fp a t h o l o g i c a lt u m o rn e c r o s i s
(95%) following an aggressive chemoradiotherapy regimen
of 28Gy administration in 8 fractions [10]. Other authors
also justiﬁed an aggressive approach to palliate distant
metastases; a wide local resection of the disseminated disease
foci followed by adjuvant radiation therapy [11, 12]. Kepka
et al. [5] described the results of radiation therapy as a sole
treatment of gross disease in 112 patients [5]. Patients who
received more than 63Gy in standard fractionation of 1.8–
2Gy achieved best local control, disease free interval, and
overall survival rate.
An animal model of a hypofractionation regimen for
macroscopicsofttissuesarcomaswascreatedandreportedby
Lawrenceetal.[13].Fourfractionsof8Gywereprescribedto
16 dogs with overt masses of STS. The overall response rate
was 50% (one complete response) with minimal side eﬀects.
Themediantimetoprogressionwas155daysandthemedian
survival time was 309 days [13].
A potential use of hypofractionated RT is in elderly or
debilitatedpopulationwithSTS.Patientswithsarcomaofthe
extremity who have a good performance status may easily
tolerate a protracted course of adjuvant RT following LSS,
even if induction chemotherapy or tumor-necrosis factor
via isolated limb perfusion had been primarily administered
[2]. However, patients with low-performance status or with
multiple comorbidities and mobility diﬃculties may be
deemed medically unﬁt for the regimen proposed herein.
While advanced age in the presence of a good performance
statusisnotalimitingfactorinthetreatmentstrategyforSTS
(LSS and RT) [2], or in other diseases (e.g., non-Hodgkin’s
lymphoma [2] and lung cancer [14]), a patient with sarcoma
andpoorperformancestatusorsevereco-morbidities,might
not be able to attend a long course of RT (5 times a week
for a total of 6–8 weeks), and might even initially give
up the important postoperative treatment. Furthermore, a
prolonged hospitalization for RT may result in unnecessary
hospital-acquired infections and social problems due to a
changeinthepatient’sclosesurroundings.OmittingRTinan
LSS-approached patient increases the risk of local recurrence
[1]. As an alternative to LSS without RT, amputation surgery
may be suggested, hampering the quality of life even more,
andrenderingthepatientbed-ridden fortherestofhislife.A
short and intense course of RT may be a logical and adequate
solution to this dilemma.
The results reported oﬀer encouraging data that can
be applied to patients suﬀering from this daunting disease.
Prospectivestudiescouldassesstheroleofhypofractionation
and other palliative strategies among debilitated or elderly
patients with STS.4 Sarcoma
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